Stroke Treatment with Ancrod Trial "STAT"

Completed

Phase 3 Results

Results

Primary endpoint, Barthel Index 95-100 at 3 months: ancrod (n=248) 41.1%, placebo (n=252) 35.2%, p=.04. No difference in mortality. Symptomatic intracranial hemorrhage, ancrod 5.2%, placebo 2% (p=ns), Efficacy and ICH rate were both increased at lower fibrinogen levels.